SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Ask Michael Burke -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (32709)9/22/1998 10:53:00 AM
From: Giuseppe Scalamogna  Read Replies (1) | Respond to of 132070
 
MB

But these short-term call premiums are awfully enticing considering we are heading into earnings preannouncement season and from what I could garner it most likely will not be a pretty sight. Some of these premiums especially on Nifty Fifty issues in my mind are blown way out of proportion. Sure the volatility has crept up, but when your line of least resistance turns over to the downside most of these contracts will expire out of the money.

Also, the biotechs in general have diverged from the rest of the market significantly. Money is flowing into some of these later stage companies with the cash burners still suffering. I see some significant upside to the mid-cap names as the large-caps such as Biogen and Amgen are in my mind a bit overpriced. We'll have to wait and see.

Thanks Again

GS



To: Knighty Tin who wrote (32709)9/22/1998 4:32:00 PM
From: Night Trader  Read Replies (1) | Respond to of 132070
 
Mike,
Are you saying calls are systematically biased in favor of the buyer? It's true that selling calls (covered ones anyway) is psychologically easier than buying them but aren't the option formulas meant to even things up?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News